Congress Asset Management Co. Buys New Shares in IQVIA Holdings Inc. $IQV

Key Points

• Congress Asset Management purchased 91,352 IQVIA shares worth approximately $24.6 million, while institutional investors collectively own 89.62% of the company.
• Analysts remain broadly optimistic: IQVIA has a “Moderate Buy” consensus rating and an average price target of $264.31, with several firms recently raising their targets.
• IQVIA reported quarterly EPS of $3.15, exceeding estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. The stock opened at $260.19, near its 52-week high of $277.40.

Congress Asset Management Co. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 91,352 shares of the medical research company's stock, valued at approximately $24,560,000. Congress Asset Management Co. owned 0.06% of IQVIA at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Miller Global Investments LLC purchased a new stake in shares of IQVIA in the third quarter worth approximately $272,000. CX Institutional boosted its stake in shares of IQVIA by 7.0% during the 3rd quarter. CX Institutional now owns 2,503 shares of the medical research company's stock valued at $673,000 after buying an additional 163 shares during the period. Versant Capital Management Inc grew its holdings in shares of IQVIA by 5.5% during the 3rd quarter. Versant Capital Management Inc now owns 2,417 shares of the medical research company's stock valued at $650,000 after acquiring an additional 126 shares in the last quarter. Burkett Financial Services LLC acquired a new position in shares of IQVIA in the third quarter worth $45,000. Finally, QRG Capital Management Inc. raised its holdings in shares of IQVIA by 87.7% during the second quarter. QRG Capital Management Inc. now owns 58,407 shares of the medical research company's stock worth $11,285,000 after acquiring an additional 27,283 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider W. Richard Staub sold 5,500 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company's stock, valued at $732,932.69. This represents a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,581 shares of company stock worth $3,796,021 in the last quarter. 1.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. TD Cowen lifted their price objective on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Stifel Nicolaus raised their price target on IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. HSBC reiterated a "buy" rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Morgan Stanley increased their price objective on IQVIA from $240.00 to $270.00 and gave the stock an "equal weight" rating in a report on Thursday, September 17th. Finally, William Blair raised shares of IQVIA to a "strong-buy" rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and an average target price of $264.31.

IQVIA Price Performance

NYSE IQV opened at $260.19 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $277.40. The stock's 50-day moving average is $256.53 and its two-hundred day moving average is $207.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market cap of $42.83 billion, a P/E ratio of 32.28, a price-to-earnings-growth ratio of 2.27 and a beta of 1.17.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the prior year, the company posted $2.81 EPS. The firm's revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.